﻿                         序列表

<110>  上海鑫湾生物科技有限公司

<120>  靶向肿瘤抗原的抗体与iNKT细胞的组合的制备方法与用途

<130>  EIC19310037P

<160>  4

<170>  SIPOSequenceListing 1.0

<210>  1
<211>  432
<212>  DNA
<213>  Artificial Sequence

<400>  1
atggaattag gcctctcttg ggtgttcctc gtggctattc tcaagggagt gcagtgcgag        60
gtgcagctgg tgcagtctgg aggcgggctc gtgcatcctg gcggctccct gagactgtct       120
tgcaccggaa gcgggttcac cttctcttac cacgctatgc actgggtgcg ccaggctcct       180
ggcaagggac tggagtgggt gagcattatc ggaaccggcg gcgtgacata ctacgctgac       240
tctgtgaagg gcagattcac aattagccgc gacaacgtga agaactccct gtacctccag       300
atgaacagcc tcagagccga ggacatggct gtgtactact gcgctagaga ctactacggc       360
gccggatctt tctacgacgg cctgtacggt atggacgtgt ggggccaggg cacaacagtg       420
accgtgtcta gc                                                           432

<210>  2
<211>  144
<212>  PRT
<213>  Artificial Sequence

<400>  2
Met Gly Leu Gly Leu Ser Thr Val Pro Leu Val Ala Ile Leu Leu Gly 
1               5                   10                  15      
Val Gly Cys Gly Val Gly Leu Val Gly Ser Gly Gly Gly Leu Val His 
            20                  25                  30          
Pro Gly Gly Ser Leu Ala Leu Ser Cys Thr Gly Ser Gly Pro Thr Pro 
        35                  40                  45              
Ser Thr His Ala Met His Thr Val Ala Gly Ala Pro Gly Leu Gly Leu 
    50                  55                  60                  
Gly Thr Val Ser Ile Ile Gly Thr Gly Gly Val Thr Thr Thr Ala Ala 
65                  70                  75                  80  
Ser Val Leu Gly Ala Pro Thr Ile Ser Ala Ala Ala Val Leu Ala Ser 
                85                  90                  95      
Leu Thr Leu Gly Met Ala Ser Leu Ala Ala Gly Ala Met Ala Val Thr 
            100                 105                 110         
Thr Cys Ala Ala Ala Thr Thr Gly Ala Gly Ser Pro Thr Ala Gly Leu 
        115                 120                 125             
Thr Gly Met Ala Val Thr Gly Gly Gly Thr Thr Val Thr Val Ser Ser 
    130                 135                 140                 

<210>  3
<211>  381
<212>  DNA
<213>  Artificial Sequence

<400>  3
atggaggctc ccgctcagct gctgttcctg ctcctgctgt ggctgcctga cacaactgga        60
gagatcgtgc tgacccagtc tcccgctaca ctgtctctga gccctggcga gcgcgccacc       120
ctgtcttgca gggcctctca gtccgtttct tcttacctcg cttggtatca gcagaagccc       180
ggacaggccc caagactcct catatatgac gcttctaacc gcgccaccgg catcccagct       240
aggttcagcg ggtccggatc tggaaccgac ttcacactca caatttctag cctcgaaccc       300
gaggacttcg ccgtgtacta ctgccagcag aggtccgact ggccactcac attcggcggc       360
gggacaaagg tggagattaa g                                                 381

<210>  4
<211>  127
<212>  PRT
<213>  Artificial Sequence

<400>  4
Met Glu Ala Pro Ala Gln Leu Leu Phe Leu Leu Leu Leu Trp Leu Pro 
1               5                   10                  15      
Asp Thr Thr Gly Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser 
            20                  25                  30          
Leu Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser 
        35                  40                  45              
Val Ser Ser Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro 
    50                  55                  60                  
Arg Leu Leu Ile Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala 
65                  70                  75                  80  
Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser 
                85                  90                  95      
Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Arg Ser 
            100                 105                 110         
Asp Trp Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 
        115                 120                 125         

